{"id":"NCT00731679","sponsor":"Bausch Health Americas, Inc.","briefTitle":"Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)","officialTitle":"A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin 550 mg TID in the Treatment of Subjects With Non-Constipation Irritable Bowel Syndrome","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-07","primaryCompletion":"2009-08","completion":"2009-09","firstPosted":"2008-08-11","resultsPosted":"2014-07-28","lastUpdate":"2019-11-29"},"enrollment":623,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Non-Constipation Irritable Bowel Syndrome"],"interventions":[{"type":"DRUG","name":"Rifaximin","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Rifaximin","type":"EXPERIMENTAL"}],"summary":"To evaluate the efficacy of a 14-day course of rifaximin given 3 times a day vs. placebo in providing adequate relief of IBS symptoms.","primaryOutcome":{"measure":"Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6).","timeFrame":"4 weeks","effectByArm":[{"arm":"Placebo","deltaMin":31.2,"sd":null},{"arm":"Rifaximin","deltaMin":40.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.01"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":96,"countries":["United States","Canada"]},"refs":{"pmids":["21208106","36922331","24697851"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":314},"commonTop":["Abdominal pain","Nausea","Headache","Diarrhoea","Nasopharyngitis"]}}